Jeanin E. van Hooft
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jeanin E. van Hooft has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Paul Fockens
Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands
13 shared publications Frank P. Vleggaar
6 shared publications- Marco J. Bruno
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
6 shared publications Paul Fockens
Univ Amsterdam, Amsterdam UMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
6 shared publications- Femme Harinck
Department of Gastroenterology & Hepatology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands
5 shared publications - Jan-Werner Poley
Maastricht University Medical Center, The Netherlands
5 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Su1336 - Pancreatic Cyst Surveillance Imposes Low Psychological Burden: Preliminary Results of the Pacyfic Study
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Su1336 - Pancreatic Cyst Surveillance Imposes Low Psychological Burden: Preliminary Results of the Pacyfic Study
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Su1338 - Outcomes after Total or Partial Pancreatectomy for Main Duct and Mixed Type-IPMN: Multicenter Retrospective Study
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Su1338 - Outcomes after Total or Partial Pancreatectomy for Main Duct and Mixed Type-IPMN: Multicenter Retrospective Study
- 1 September 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (5) , 800-806
Systematic review and meta-analysis on the prevalence of vitamin D deficiency in patients with chronic pancreatitis
- 1 September 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (5) , 800-806
Systematic review and meta-analysis on the prevalence of vitamin D deficiency in patients with chronic pancreatitis
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e15738
Multimodality treatment of 132 consecutive patients with locally advanced pancreatic cancer.
E15738 Background: FOLFIRINOX and irreversible electroporation(IRE) show promising results for locally advanced pancreatic cancer(LAPC). However, most studies only include patients with stable disease under chemotherapy. Our aim was to describe outcomes of multimodality treatment with FOLFIRINOX-chemotherapy, surgical exploration and IRE in a complete LAPC-cohort. Methods: Prospective single-center cohort (09.2013-03.2015), including all consecutive histologically proven LAPC-patients ( > 90°arterial or > 270°venous involvement). Preferred chemotherapy consisted of FOLFIRINOX, or, if unfeasible, gemcitabine. Radiotherapy was only used for local pain control. After three months, restaging was performed to assess RECIST1.1-response, radiological resectability and IRE-eligibility (tumor ≤ 5cm). All patients with non-progressive disease (RECIST) and IRE-eligible tumors underwent explorative laparotomy. Results: Of 132 patients with LAPC, 70% (n = 93) received chemotherapy (63% (n = 59) FOLFIRINOX). After 3 months, 45% (n = 59/132) had non-progressive disease. Of all 132 patients, 27% (n = 36) underwent surgical exploration with a resection in 11% (n = 14/132, R0 8/14) and IRE in 11% (n = 15/132). After surgical exploration, the Clavien-Dindo grade ≥ 3 complication rate was 39% (6/14 resection, 7/15 IRE, 1/7 other) and 90-day mortality 11% (1/14 resection, 2/15 IRE, 1/7 other). Median overall survival (mOS) and 1-year cumulative survival from diagnosis were 11 months and 43% respectively for all patients, 19 months and 71% for patients with non-progressive disease, 23 months and 82% in resected patients, and 16 months and 71% in IRE patients, with a median follow up of 10 months. Conclusions: A multimodality approach to LAPC is feasible with acceptable outcomes, especially in patients receiving FOLFIRINOX. This study highlights the importance of reporting on the outcomes of consecutive rather than selected cohorts of LAPC. Final survival data will have to be awaited before the added value of IRE can be evaluated. Clinical trial information: NTR4230.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e15738
Multimodality treatment of 132 consecutive patients with locally advanced pancreatic cancer.
E15738 Background: FOLFIRINOX and irreversible electroporation(IRE) show promising results for locally advanced pancreatic cancer(LAPC). However, most studies only include patients with stable disease under chemotherapy. Our aim was to describe outcomes of multimodality treatment with FOLFIRINOX-chemotherapy, surgical exploration and IRE in a complete LAPC-cohort. Methods: Prospective single-center cohort (09.2013-03.2015), including all consecutive histologically proven LAPC-patients ( > 90°arterial or > 270°venous involvement). Preferred chemotherapy consisted of FOLFIRINOX, or, if unfeasible, gemcitabine. Radiotherapy was only used for local pain control. After three months, restaging was performed to assess RECIST1.1-response, radiological resectability and IRE-eligibility (tumor ≤ 5cm). All patients with non-progressive disease (RECIST) and IRE-eligible tumors underwent explorative laparotomy. Results: Of 132 patients with LAPC, 70% (n = 93) received chemotherapy (63% (n = 59) FOLFIRINOX). After 3 months, 45% (n = 59/132) had non-progressive disease. Of all 132 patients, 27% (n = 36) underwent surgical exploration with a resection in 11% (n = 14/132, R0 8/14) and IRE in 11% (n = 15/132). After surgical exploration, the Clavien-Dindo grade ≥ 3 complication rate was 39% (6/14 resection, 7/15 IRE, 1/7 other) and 90-day mortality 11% (1/14 resection, 2/15 IRE, 1/7 other). Median overall survival (mOS) and 1-year cumulative survival from diagnosis were 11 months and 43% respectively for all patients, 19 months and 71% for patients with non-progressive disease, 23 months and 82% in resected patients, and 16 months and 71% in IRE patients, with a median follow up of 10 months. Conclusions: A multimodality approach to LAPC is feasible with acceptable outcomes, especially in patients receiving FOLFIRINOX. This study highlights the importance of reporting on the outcomes of consecutive rather than selected cohorts of LAPC. Final survival data will have to be awaited before the added value of IRE can be evaluated. Clinical trial information: NTR4230.
- Open Access
- 13 May 2016
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 51 (9) , 1138-1143
Long-term follow-up of neoplastic pancreatic cysts without high-risk stigmata: how often do we change treatment strategy because of malignant transformation?
*Objective: Patients with potentially premalignant neoplastic pancreatic cysts without high-risk stigmata usually enter a surveillance program. Data on outcomes of such surveillance programs are scarce. We aimed to evaluate the resection rate and malignancy rate during follow-up. Material and methods: From our prospective database (2006–2015) of patients with pancreatic cysts, we analyzed patients with pancreatic cysts without high-risk stigmata with at least six months follow-up. Results: In total, 146 patients were followed for a median of 29 months (IQR 13.5–50 months). In 124 patients (84.9%), no changes in clinical or imaging characteristics occurred during follow-up. Thirteen patients (8.9%) developed an indication for surgery after a median follow-up of 25 months (IQR 12–42 months). Two patients did not undergo surgery because of comorbidity, 11 patients (7.5%) underwent resection. Indications for surgery were symptoms (n = 2), development of a pancreatic mass (n = 1), a new nodule (n = 2), thickened cyst wall (n = 1), pancreatic duct dilation (n = 3), and/or suspicion of mucinous cystic neoplasm (MCN) (n = 3). Postoperative histology showed one pancreatic malignancy not originating from the cyst, three mixed type-intraductal papillary mucinous neoplasm (IPMN), one side branch-IPMN, two MCN, one neuroendocrine tumor, one serous cystadenoma, one inflammatory cyst, and one lymphangioma. The highest grade of cyst dysplasia was borderline dysplasia. Conclusions: Most neoplastic pancreatic cysts without high-risk stigmata at initial presentation show no substantial change during 1–4-year follow-up. Only 7.5% of patients underwent surgery and less than 1% of patients developed pancreatic malignancy. This indicates that additional markers are needed to tailor treatment of pancreatic cysts.
- 13 May 2016
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 51 (9) , 1138-1143
Open AccessLong-term follow-up of neoplastic pancreatic cysts without high-risk stigmata: how often do we change treatment strategy because of malignant transformation?
*Objective: Patients with potentially premalignant neoplastic pancreatic cysts without high-risk stigmata usually enter a surveillance program. Data on outcomes of such surveillance programs are scarce. We aimed to evaluate the resection rate and malignancy rate during follow-up. Material and methods: From our prospective database (2006–2015) of patients with pancreatic cysts, we analyzed patients with pancreatic cysts without high-risk stigmata with at least six months follow-up. Results: In total, 146 patients were followed for a median of 29 months (IQR 13.5–50 months). In 124 patients (84.9%), no changes in clinical or imaging characteristics occurred during follow-up. Thirteen patients (8.9%) developed an indication for surgery after a median follow-up of 25 months (IQR 12–42 months). Two patients did not undergo surgery because of comorbidity, 11 patients (7.5%) underwent resection. Indications for surgery were symptoms (n = 2), development of a pancreatic mass (n = 1), a new nodule (n = 2), thickened cyst wall (n = 1), pancreatic duct dilation (n = 3), and/or suspicion of mucinous cystic neoplasm (MCN) (n = 3). Postoperative histology showed one pancreatic malignancy not originating from the cyst, three mixed type-intraductal papillary mucinous neoplasm (IPMN), one side branch-IPMN, two MCN, one neuroendocrine tumor, one serous cystadenoma, one inflammatory cyst, and one lymphangioma. The highest grade of cyst dysplasia was borderline dysplasia. Conclusions: Most neoplastic pancreatic cysts without high-risk stigmata at initial presentation show no substantial change during 1–4-year follow-up. Only 7.5% of patients underwent surgery and less than 1% of patients developed pancreatic malignancy. This indicates that additional markers are needed to tailor treatment of pancreatic cysts.
- 1 May 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (5) , e9-e11
Skin Lesion After Endoscopic Pseudocyst Drainage
- 1 May 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (5) , e9-e11
Skin Lesion After Endoscopic Pseudocyst Drainage
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S362-S363
Sa1773 Factors Associated With Cancer Worries in Individuals Participating in Annual Pancreatic Cancer Surveillance
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S362-S363
Sa1773 Factors Associated With Cancer Worries in Individuals Participating in Annual Pancreatic Cancer Surveillance